Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005–13

Background: Erythropoiesis-stimulating agents (ESAs) with intravenous iron supplementation are the main treatment for anaemia in patients with chronic kidney disease. Although observational studies suggest better outcomes for patients who achieve higher haemoglobin (Hb) levels, randomized controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Birnie, Kate, Caskey, Fergus, Ben-Shlomo, Yoav, Sterne, Jonathan A.C., Gilg, Julie, Nitsch, Dorothea, Tomson, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410985/
https://www.ncbi.nlm.nih.gov/pubmed/27190350
http://dx.doi.org/10.1093/ndt/gfw043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410985/
https://www.ncbi.nlm.nih.gov/pubmed/27190350
http://dx.doi.org/10.1093/ndt/gfw043

Ejemplares similares